Segments (Tables)

9 Months Ended

Sep. 30, 2025

Summary of Significant Expense Categories and Asset Categories

The table below summarizes the significant expense categories regularly reviewed by the CODM for the nine month periods ended September 30, 2025 and 2024 (in thousands).


	Nine Months Ended June 30,
		2025			2024
	(in thousands)
Operating expenses:
Research and development	$	12,357		$	25,462
General and administrative		4,363			4,543
Total operating expenses		16,720			30,005
Total operating loss		(16,720	)		(30,005	)
Other income (expense):
Interest income		101			254
Interest expense		(5,390	)		(3,815	)
Change in fair value of derivatives		(3,327	)		(1,514	)
Total other expense		(8,616	)		(5,075	)
Net loss	$	(25,336	)	$	(35,080	)
Preferred stock dividends		(76	)		(90	)
Net loss applicable to common stockholders	$	(25,412	)	$	(35,170	)

The table below summarizes the significant asset categories regularly reviewed by the CODM as of September 30, 2025 and December 31, 2024 (in thousands).


		September 30, 2025		December 31, 2024
	(in thousands)
Cash and cash equivalents	$	11,525	$	15,120

GALECTIN THERAPEUTICS INC 10-Q